{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:55:19Z","timestamp":1781769319439,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"DOI":"10.1007\/s00431-026-07003-4","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:16:26Z","timestamp":1778156186000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Piperacillin-tazobactam versus cefepime monotherapy in pediatric patients with febrile neutropenia: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2704-4588","authenticated-orcid":false,"given":"Bernardo Lu\u00eds Giacomelli","family":"Fernandes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0566-8360","authenticated-orcid":false,"given":"Allan","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4353-8173","authenticated-orcid":false,"given":"V\u00edtor Honorato","family":"Andriazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"7003_CR1","unstructured":"Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, Sinha IP, Thomas N et al (2024) Cochrane handbook for systematic reviews of interventions, version 6.5 (updated August 2024). Cochrane, 2024. Available from https:\/\/www.cochrane.org\/handbook. Accessed 3 Feb 2026"},{"key":"7003_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"7003_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"7003_CR4","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2025","unstructured":"R Core Team (2025) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria"},{"key":"7003_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135","journal-title":"BMC Med Res Methodol"},{"key":"7003_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"7003_CR7","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software] (2023) McMaster University and Evidence Prime. Available from https:\/\/gradepro.org. Accessed 3 Feb 2026."},{"key":"7003_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/0049475515617571","volume":"46","author":"M Aamir","year":"2016","unstructured":"Aamir M, Abrol P, Sharma D, Punia H (2016) A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of North India. Trop Doct 46:142\u2013148. https:\/\/doi.org\/10.1177\/0049475515617571","journal-title":"Trop Doct"},{"key":"7003_CR9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/08880010500506370","volume":"23","author":"F Corapcioglu","year":"2006","unstructured":"Corapcioglu F, Sarper N, Zengin E (2006) Monotherapy with piperacillin\/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison. Pediatr Hematol Oncol 23:177\u2013186. https:\/\/doi.org\/10.1080\/08880010500506370","journal-title":"Pediatr Hematol Oncol"},{"key":"7003_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/pbc.25178","volume":"62","author":"H Sano","year":"2015","unstructured":"Sano H, Kobayashi R, Suzuki D, Kishimoto K, Yasuda K, Kobayashi K (2015) Comparison between piperacillin\/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: a prospective, randomized study. Pediatr Blood Cancer 62:356\u2013358. https:\/\/doi.org\/10.1002\/pbc.25178","journal-title":"Pediatr Blood Cancer"},{"key":"7003_CR11","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/pbc.22100","volume":"53","author":"V Uygun","year":"2009","unstructured":"Uygun V, Karasu GT, Ogunc D, Yesilipek A, Hazar V (2009) Piperacillin\/tazobactam versus cefepime for the empirical treatment of pediatric cancer patients with neutropenia and fever: a randomized and open-label study. Pediatr Blood Cancer 53:610\u2013614. https:\/\/doi.org\/10.1002\/pbc.22100","journal-title":"Pediatr Blood Cancer"},{"key":"7003_CR12","doi-asserted-by":"publisher","first-page":"8550","DOI":"10.1200\/JCO.2005.23.16_suppl.8550","volume":"23","author":"R Kebudi","year":"2005","unstructured":"Kebudi R, Ayan I, G\u00f6rg\u00fcn \u00d6, G\u00fcrler N (2005) Piperacillin-tazobactam versus cefepime monotherapy for pediatric febrile neutropenia. J Clin Oncol 23:8550. https:\/\/doi.org\/10.1200\/JCO.2005.23.16_suppl.8550","journal-title":"J Clin Oncol"},{"key":"7003_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1086\/505393","volume":"43","author":"EJ Bow","year":"2006","unstructured":"Bow EJ, Rotstein C, Noskin GA, Laverdi\u00e8re M, Schwarer AP, Segal BH, Seymour JF, Szer J, S\u00e1nchez S (2006) A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin-tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 43:447\u2013459. https:\/\/doi.org\/10.1086\/505393","journal-title":"Clin Infect Dis"},{"key":"7003_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028253","volume":"100","author":"X Liang","year":"2021","unstructured":"Liang X, Li X, Huang H (2021) Comparative efficacy and safety of antipseudomonal \u03b2-lactams for pediatric febrile neutropenia: a systematic review and Bayesian network meta-analysis. Medicine (Baltimore) 100:e28253. https:\/\/doi.org\/10.1097\/MD.0000000000028253","journal-title":"Medicine (Baltimore)"},{"key":"7003_CR15","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1007\/s00520-011-1333-3","volume":"20","author":"A Manji","year":"2012","unstructured":"Manji A, Lehrnbecher T, Dupuis LL, Beyene J, Sung L (2012) A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. Support Care Cancer 20:2295\u20132304. https:\/\/doi.org\/10.1007\/s00520-011-1333-3","journal-title":"Support Care Cancer"},{"key":"7003_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00520-003-0463-7","volume":"11","author":"M Gorschl\u00fcter","year":"2003","unstructured":"Gorschl\u00fcter M, Hahn C, Fixson A, Mey U, Ziske C, Molitor E, Horr\u00e9 R, Sauerbruch T, Marklein G, Schmidt-Wolf IGH et al (2003) Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison. Support Care Cancer 11:362\u2013370. https:\/\/doi.org\/10.1007\/s00520-003-0463-7","journal-title":"Support Care Cancer"},{"key":"7003_CR17","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/pbc.23106","volume":"57","author":"M Ichikawa","year":"2011","unstructured":"Ichikawa M, Suzuki D, Ohshima J, Cho Y, Kaneda M, Iguchi A, Ariga T (2011) Piperacillin\/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia. Pediatr Blood Cancer 57:1159\u20131162. https:\/\/doi.org\/10.1002\/pbc.23106","journal-title":"Pediatr Blood Cancer"},{"key":"7003_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1089\/mdr.2014.0092","volume":"21","author":"SB Han","year":"2015","unstructured":"Han SB, Jung SW, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH, Kim HK et al (2015) Extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children. Microb Drug Resist 21:244\u2013251. https:\/\/doi.org\/10.1089\/mdr.2014.0092","journal-title":"Microb Drug Resist"},{"key":"7003_CR19","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2014.045","volume":"6","author":"AR Nateghian","year":"2014","unstructured":"Nateghian AR, Robinson JL, Vosough P, Navidinia M, Malekan M, Mehrvar A, Sobouti B, Bahadoran P, Gholinejad Z (2014) Comparison of antimicrobial sensitivity to older and newer quinolones versus piperacillin-tazobactam, cefepime and meropenem in febrile patients with cancer in two referral pediatric centers in Tehran, Iran. Mediterr J Hematol Infect Dis 6:e2014045. https:\/\/doi.org\/10.4084\/MJHID.2014.045","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"7003_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/ped.12025","volume":"55","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Ito M, Sano H, Mochizuki K, Akaihata M, Waragai T, Hosoya M, Kikuta A (2013) Clinical analysis of combination therapy for febrile neutropenic patients in childhood cancer. Pediatr Int 55:65\u201371. https:\/\/doi.org\/10.1111\/ped.12025","journal-title":"Pediatr Int"},{"key":"7003_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10096-010-0879-1","volume":"29","author":"L G\u00f3mez","year":"2010","unstructured":"G\u00f3mez L, Estrada C, G\u00f3mez I, M\u00e1rquez M, Estany C, Mart\u00ed JM, Bast\u00fas R, Cirera L, Quintana S, Garau J (2010) Low-dose beta-lactam plus amikacin in febrile neutropenia: cefepime vs. piperacillin\/tazobactam, a randomized trial. Eur J Clin Microbiol Infect Dis 29:417\u2013427. https:\/\/doi.org\/10.1007\/s10096-010-0879-1","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"7003_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jiac.2017.03.020","volume":"23","author":"H Teranishi","year":"2017","unstructured":"Teranishi H, Koga Y, Nishio H, Kato W, Ono H, Kanno S, Nakashima K, Takada H (2017) Clinical efficacy of cycling empirical antibiotic therapy for febrile neutropenia in pediatric cancer patients. J Infect Chemother 23:463\u2013467. https:\/\/doi.org\/10.1016\/j.jiac.2017.03.020","journal-title":"J Infect Chemother"},{"key":"7003_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0208039","volume":"13","author":"BH Tan","year":"2018","unstructured":"Tan BH, Guzman MRTD, Donato LKS, Kalimuddin S, Lee WHL, Tan AL, Wong GC (2018) Impact of an alternating first-line antibiotics strategy in febrile neutropenia. PLoS One 13:e0208039. https:\/\/doi.org\/10.1371\/journal.pone.0208039","journal-title":"PLoS One"},{"key":"7003_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27750","volume":"66","author":"HT Quach","year":"2019","unstructured":"Quach HT, Esbenshade AJ, Zhao Z, Banerjee R (2019) Incidence of acute kidney injury among pediatric hematology\/oncology patients receiving vancomycin in combination with piperacillin\/tazobactam or cefepime. Pediatr Blood Cancer 66:e27750. https:\/\/doi.org\/10.1002\/pbc.27750","journal-title":"Pediatr Blood Cancer"},{"key":"7003_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/jpids\/piy030","volume":"8","author":"KM Cook","year":"2019","unstructured":"Cook KM, Gillon J, Grisso AG, Banerjee R, Jimenez-Truque N, Phillips EJ, Van Driest SL (2019) Incidence of nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin\u2013tazobactam or cefepime: a cohort study. J Pediatr Infect Dis Soc 8:221\u2013227. https:\/\/doi.org\/10.1093\/jpids\/piy030","journal-title":"J Pediatr Infect Dis Soc"},{"key":"7003_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s15010-020-01462-z","volume":"48","author":"M Scheler","year":"2020","unstructured":"Scheler M, Lehrnbecher T, Groll AH, Volland R, Laws HJ, Ammann RA, Agyeman P, Attarbaschi A, Lux M, Simon A (2020) Management of children with fever and neutropenia: results of a survey in 51 pediatric cancer centers in Germany, Austria, and Switzerland. Infection 48:607\u2013618. https:\/\/doi.org\/10.1007\/s15010-020-01462-z","journal-title":"Infection"},{"key":"7003_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/ped.15276","volume":"64","author":"P Prasopchoknapaporn","year":"2022","unstructured":"Prasopchoknapaporn P, Boonsathorn S, Techasaensiri C, Chaisavaneeyakorn S, Apiwattanakul N (2022) Pediatric drug utilization evaluation of cefepime and piperacillin\/tazobactam. Pediatr Int 64:e15276. https:\/\/doi.org\/10.1111\/ped.15276","journal-title":"Pediatr Int"},{"key":"7003_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.anai.2021.05.009","volume":"127","author":"C Naureckas Li","year":"2021","unstructured":"Naureckas Li C, Fu X, Mancini CM, Zhang Y, Blumenthal KG (2021) Association of beta-lactam allergy documentation and antibiotic use in patients with febrile neutropenia. Ann Allergy Asthma Immunol 127:275\u2013277. https:\/\/doi.org\/10.1016\/j.anai.2021.05.009","journal-title":"Ann Allergy Asthma Immunol"},{"key":"7003_CR29","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.jpeds.2010.03.023","volume":"157","author":"EE Adderson","year":"2010","unstructured":"Adderson EE, Flynn PM, Hoffman JM (2010) Efficacy and safety of cefepime in pediatric patients: a systematic review and meta-analysis. J Pediatr 157:490\u2013495. https:\/\/doi.org\/10.1016\/j.jpeds.2010.03.023","journal-title":"J Pediatr"},{"key":"7003_CR30","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10096-007-0382-5","volume":"26","author":"A Simon","year":"2007","unstructured":"Simon A, Lehrnbecher T, Bode U, Groll AH, Tramsen L, Wieland R, Molitor E, Fleischhack G, Laws HJ (2007) Piperacillin-tazobactam in pediatric cancer patients younger than 25 months: a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 26:801\u2013806. https:\/\/doi.org\/10.1007\/s10096-007-0382-5","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"7003_CR31","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJM199305063281808","volume":"328","author":"PA Pizzo","year":"1993","unstructured":"Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323\u20131332. https:\/\/doi.org\/10.1056\/NEJM199305063281808","journal-title":"N Engl J Med"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-026-07003-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-026-07003-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:33:37Z","timestamp":1781768017000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-026-07003-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["7003"],"URL":"https:\/\/doi.org\/10.1007\/s00431-026-07003-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8882376\/v1","asserted-by":"object"}]},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"(\u201cfebrile neutropenia\u201d OR \u201cneutropenic fever\u201d OR \u201cfever and neutropenia\u201d OR (\u201cfever\u201d AND neutropenia) OR \u201cneutropenic sepsis\u201d) AND (pediatric OR paediatric OR child OR children OR adolescent OR infant OR neonate OR newborn OR \u201cyoung patient*\u201d) AND (cefepime) AND (\u201cpiperacillin\u2013tazobactam\u201d OR \u201cpiperacillin-tazobactam\u201d OR pip-tazo OR piptazo OR TZP OR PTZ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Full search string"}}],"article-number":"358"}}